JAK3/BTK-IN-4
JAK3/BTK-IN-4 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-4 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, compound 003) [1]
Product Specifications
CAS Number
[2673196-38-6]
UNSPSC
12352005
Target
Btk; JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/jak3-btk-in-4.html
Solubility
10 mM in DMSO
Smiles
C=CC(N(CCC1)CC21CCN2C3=C4C(NC=C4Cl)=NC(NC5=CN(CC)N=C5)=N3)=O
Molecular Formula
C21H25ClN8O
Molecular Weight
440.93
References & Citations
[1]Baoguo Zhang, et al. Pyrimidinopyrimidine and pentacyclic derivatives and their applications. Patent WO2021147953A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Fc Fragment of IgG, Low Affinity IIa, Receptor / CD32 (FCGR2A) Antibody (Biotin)
Fc Fragment of IgG, Low Affinity IIa, Receptor / CD32 (FCGR2A) Antibody (Biotin)